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Introduction
Glioblastoma multiforme (GBM; World Health 
Organization, WHO, grade IV tumor) is the most malignant 
form of brain cancer with a median survival of 15 months 
[1]. GBMs, are characterized by uncontrolled proliferation, 
diffuse infiltration of adjacent tissues, high genomic instabil-
ity, and resistance to radio- and chemotherapy, all features 
that are useful prognostic factors for overall survival. 
Putative genetic and epigenetic prognostic factors have been 
investigated in order to optimize treatment strategies. These 
include 1p/19q codeletion, isocitrate dehydrogenase (IDH) 
1 and 2 gene (IDH1/2) mutations, and methylation of the 
O(6)- methylguanine- DNA methyltransferase (MGMT) pro-
moter [2, 3], which confer a better responsiveness to radio-
 and chemotherapy [4–6], even the disease is still incurable. 
A prominent feature of GBM is the aberrant angiogenesis. 
Indeed, GBM is considered the most hypervascularized 
tumor with activation of multiple proangiogenic signaling 
pathways that enhance tumor growth. In GBM patients, 
microvascular density has been correlated with postopera-
tive survival [7]. The identification of prognostic markers 
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Circulating biomarker for malignant gliomas could improve both differential 
diagnosis and clinical management of brain tumor patients. Among all gliomas, 
glioblastoma (GBM) is considered the most hypervascularized tumor with acti-
vation of multiple proangiogenic signaling pathways that enhance tumor growth. 
To investigate whether preoperative antigen plasma level of von Willebrand 
Factor (VWF:Ag) might be possible marker for GBM onset, progression, and 
prognosis, we retrospectively examined 57 patients with histological diagnosis 
for GBM and 23 meningiomas (MNGs), benign intracranial expansive lesions, 
enrolled as controls. Blood samples were collected from all the patients before 
tumor resection. Plasma von Willebrand Factor (VWF):Ag levels were determined 
by using a latex particle- enhanced immunoturbidimetric assay. The median levels 
of vWF:Ag were significantly higher in GBMs than in meningiomas (MNGs) 
(183 vs. 133 IU/dL, P = 0.01). The cumulative 1- year survival was significantly 
shorter in patients with VWF:Ag levels >200 IU/dL than in those with levels 
<200 IU/dL and increased VWF levels were associated with a threefold higher 
risk of death in GBM patients. Our data suggest that VWF:Ag could be a 
circulating biomarker of disease malignancy, that could be considered, in asso-
ciation with other genetic and epigenetic factors, currently available in the GBM 
management. Future studies should investigate whether plasma VWF:Ag levels 
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for GBM in more accessible specimens, such as blood, would 
be of help in the treatment of patients accompanied to the 
aforementioned genetic/epigenetic factors.
In the last years, new proteomic approaches allow the 
identification of circulating plasma proteins which reflect 
disease biology, and have been considered a useful option 
to discover potential biomarkers for brain tumors [8]. 
Among the most relevant candidates, angiogenic factors, 
have been found to play a pivotal role in GBM onset 
and progression [9].
In this context, von Willebrand factor (VWF), a mul-
timeric glycoprotein that carries coagulation factor VIII 
in plasma, participates in coagulation process, in hemo-
stasis, and in negative modulation of angiogenesis [10]. 
Besides these roles, VWF may also have proangiogenic 
properties. Yang and colleagues reported that higher mRNA 
and protein expression of VWF in gastric cancer (GC) 
tumor stroma may be regulated by the VEGF- VEGFR2 
signaling pathway in vitro and may contribute to GC 
progression in vivo [11]. Moreover, Randi suggested that 
the mechanism of action of VWF in the control of angio-
genesis involves enhanced signaling from the growth factor 
receptor VEGFR2. VWF was found to regulate two path-
ways, possibly linked, which may be controlling angio-
genesis: an extracellular pathway involving integrin αvβ3 
and an intracellular pathway involving Ang- 2 storage in 
Weibel–Palade bodies (WPB). Both these pathways have 
been shown to influence VEGF signaling [10]. Recently, 
VWF has been considered a potential circulating marker 
for tumor angiogenesis in different types of cancer [12]. 
VWF is synthesized and released into the blood stream 
by endothelial cells, where it is also stored in the WPB 
from which it can be rapidly released upon stimulation 
[13]. Several reports have described a direct interaction 
between VWF and tumor cells [14, 15], and a direct 
relationship between staining intensity of VWF in microves-
sels and different grades of astrocytomas [7].
The objective of this study was to evaluate the potential 
role of preoperative plasma levels of VWF in prognosis of 
GBM, in combination with the GBM molecular profile.
At this purpose, VWF antigen (VWF:Ag) plasma levels 
were evaluated in a cohort of patients affected with GBM 
and compared with a group of patients affected with 
meningiomas (MNGs), benign intracranial expansive 
lesions, in order to evaluate whether or not a correlation 
exists between VWF levels and disease prognosis.
Materials and Methods
Study population
A total of 57 patients with newly diagnosed GBM and 
23 patients with MNGs, enrolled as controls, who had 
undergone neurosurgical procedures at the Neurosurgery 
Unit of the Fondazione IRCCs Ca’ Granda Ospedale 
Policlinico in the last 3 years were included in the study. 
All tumors had been examined histopathologically and 
classified according to the WHO classification. 
Demographic and clinical data were retrospectively col-
lected from patients’ files, starting from the date of diag-
nosis until death or the date of the last visit performed, 
whichever came first. Karnofsky performance status (KPS) 
was assessed on the day before surgery, at which time, 
the collection of blood sample was performed. Written 
informed consent for blood sampling and molecular analy-
ses was obtained from patients. The study was approved 
by the Institutional Review Board.
Blood sample collection and VWF:Ag levels 
determination
Blood samples were taken from each subject prior to any 
treatment. Blood was drawn into tubes with sodium citrate 
anticoagulant and centrifuged and the supernatants were 
stored at −70°C until the levels of VWF:Ag were assessed. 
VWF:Ag levels were determined blind to the clinical data 
and were measured in plasma samples by using a latex 
particle- enhanced immunoturbidimetric assay (Instru-
mental Laboratory, Orangeburg, NY) with a normal range 
of 40–169 IU/dL for O blood group and 55–165 IU/dL 
for non- O blood groups.
Molecular characterization of the tumor
Genomic DNA was extracted from peripheral blood lym-
phocytes (PBL) using the QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instruc-
tions. Tumor DNA was isolated from paraffin- embedded 
tissue fragments using the Biostic FFPE tissue DNA isola-
tion Kit (MO BIO Laboratories, Carlsbad, CA), following 
manufacturer’s instructions.
Loss of heterozygosity (LOH) of chromosome arms 1p 
and 19q was assessed by short tandem repeats (STR: 
D1S468, D1S548, D1S2666, D1S1612, D19S918, D19S596, 
D19S206) analysis using paired tumor specimens and PBLs. 
Criteria used to establish LOH were the same as reported. 
[16]. The IDH1 codon 132 and IDH2 codon 172 muta-
tions were screened by MassArray iPLEX platform (Agena 
Bioscience, Hamburg, Germany) based on matrix- assisted 
laser desorption ionization time- of- flight (MALDI- TOF) 
mass spectrometry. PCR multiplex amplification was con-
ducted in a 5 μL reaction mixture containing 30 ng of 
tumor DNA, 100 nmol/L each designed primers, 
100 nmol/L dNTP mix, PCR buffer, 25 mmol/L MgCl2, 
and 5U Taq DNA polymerase (Agena Bioscience). The 
mixture was incubated as follows: 95°C for 2 min, 45 
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cycles of 95°C for 30 sec, 56°C for 30 sec, 72°C for 60 sec, 
and then a final extension step at 72°C for 5 min. Plates 
were incubated at 37°C for 40 min and then at 85°C for 
5 min. Finally, the iPLEX reaction mix, including iPLEX 
Buffer Plus, iPLEX Termination Mix, Extended Primers 
mix, and iPLEX enzyme (Agena Bioscience), was added 
to the PCR amplification products. The iPLEX reaction 
was carried out in the following conditions: at 94°C for 
30 sec; 40 cycles at 94°C for 5 sec [52°C for 5 sec and 
80°C for 5 sec (repeated five times per cycle)]; and a 
final extension step at 72°C for 3 min. The samples were 
spotted on a SpectroCHIP (Agena Bioscience). The chip 
was analyzed by mass spectrometry. The spectrum profiles 
generated by MALDI- TOF- MS were acquired and examined 
with SpectroTYPER 4.0 software (Sequenom, Inc., San 
Diego, CA). Moreover, tumor DNAs were subjected to 
conversion using the EZ DNA Methylation- Gold Kit (Zymo 
Research Corporation, Irvine, CA). A total of 50–100 ng 
of DNA was amplified by PCR using 10 pmol of forward 
(5′- GTTTYGGATATGTTGGGATAG- 3′) and reverse prim-
ers (5′- bioCRACCCAAACACTCACCAAA- 3′). The PCR 
conditions for MGMT gene were: 95°C for 5 min, 45 
cycles of 95°C for 30 sec, 56°C for 30 sec, and 72°C for 
20 sec. Quantitative DNA methylation analysis of 10 CpGs 
(CpGs 74- 83) [17] was performed on the Pyro Mark ID 
instrument using the Pyro Gold Reagents and 1 pmol of 
sequencing primer (5′- GATAGTTYGYGTTTTTAGAA- 3′).
Tumor volume measurement
The tumor volume of each GBM patient was calculated 
from preoperative, post- contrast T1- weighted magnetic 
resonance images (MRI). The ellipsoid volume equation 
(AxBxC)/2, in which A, B, and C represent the three 
dimensions of the enhancing lesion detectable [18] was 
used. The MRI scans had been performed no more than 
14 days before blood sampling.
Statistical analysis
Continuous variables were expressed as median values and 
interquartile ranges (IQR), and compared by the Mann–
Whitney U- test. Categorical variables were expressed as 
frequencies and percent values, and compared by the 
chi- squared test. Mortality rates with 95% confidence 
intervals (95% CI) were calculated as the number of events 
per 1 person- year. Survival curves were plotted with the 
Kaplan–Meier method and analyzed by using the log- rank 
test. For survival and regression analyses, VWF:Ag levels 
were categorized setting the cutoff level at the upper nor-
mal limit (165 IU/dL) and at supraphysiological levels 
(200 and 250 IU/dL). For the same purpose, the tumor 
volume was categorized by choosing as cutoff the median 
value observed in the study population (i.e., 25 cm3). 
Rho correlation coefficients were calculated by the 
Spearman’s test. The Cox proportional hazard model was 
used to estimate potential risk factors of death and the 
effect of each variable was adjusted for the others in the 
multivariate model. In this model, death was the event 
and follow- up duration was the time variable. The follow-
 up period for each patient was calculated starting from 
the date of diagnosis to death or last visit at time of 
medical files review, whichever came first. Putative risk 
factors for reduced overall survival were VWF:Ag levels 
>200 IU/dL, age at surgery >60 years, preoperative KPS 
<70, tumor volume >25 cm3, methylated MGMT pro-
moter, absence of 1p/19q deletion, and wild- type IDH1/2. 
The results were expressed as crude and adjusted hazard 
ratios (cHR and aHR) with 95% CI. Starting with the 
full model, stepwise backward elimination was used as a 
variable selection procedure. A nominal α level of 0.10 
as a cutoff for removing variables was considered. All 
P- values reported are two- sided and a value <0.05 was 
considered statistically significant. All analyses were done 
with SPSS software (release 21.0, IBM Corp., Armonk, 
New York).
Results
Characteristics of the study population
Overall, 80 patients who underwent neurosurgical proce-
dures for GBMs or MNGs between February 2012 and 
June 2015 were included in the study. All patients under-
went surgical resection of the lesion obtaining a gross 
total resection, except for two patients who underwent 
biopsy owing to tumor localization. All GBM patients 
received 6- week treatment by radiotherapy (RT) with 
concomitant systemic therapy using alkylating agent, temo-
zolomide (TMZ). In detail, standard treatment involved 
the administration total of 60 Gy in 30–35 fractions of 
1.8–2.0 Gy, 5 days a week. Concomitant TMZ was admin-
istered 75 mg/m2/day during RT, and after 150-200 mg/
m2/day for 5 days every 28 days for 12 cycles [19]. The 
main characteristics of the 80 patients at study entry are 
reported in Table 1. Blood group was known in 51 patients 
(64%), being O in 34 (43%). Since VWF tends to be 
lower in individuals with O blood groups [20], we ana-
lyzed separately VWF levels in both blood groups, and 
in spite of everything in GBM patients with O group, 
the levels were still higher respect to MNGs (median 
250 IU/dL, IQR 175.50–355 vs. 164 IU/dL, IQR 121–200). 
Moreover, the same proportion of O/non- O blood group 
was found analyzing separately patients with MNG and 
those with GBMs. Overall, the median preoperative KPS 
was 80 (IQR: 70–90) and it was inversely correlated with 
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age (r = −0.43, P < 0.0001). In GBM patients, the median 
volume of the tumoral lesion was 25.6 cm3 (IQR: 8.0–45.3). 
The cumulative 1- year survival was significantly shorter 
in patients with the bigger tumor volume at the end of 
the follow- up period (median 32.5 vs. 23.4 cm3; IQR: 
16.3–53.0 vs. 6.4–35.0, respectively; P = 0.04).
Plasma VWF:Ag levels in GBM and MNG 
patients
VWF:Ag levels were significantly higher in patients with 
GBM than in those with MNG (median 177 IU/dL, IQR: 
135–294 vs. 133 IU/dL, IQR: 101–190, respectively; 
P = 0.01) (Fig. 1A). No differences were found by com-
paring VWF:Ag levels in patients with O versus non- O 
blood group. VWF:Ag levels were linearly correlated with 
age both in patients with GBM (r = 0.40; P = 0.001) 
and in those with MNG (r = 0.45; P = 0.03). Moreover, 
when our cohort was divided into patients above 60 years 
and younger, we found that VWF:Ag levels were signifi-
cantly higher in GBMs than in MNGs despite the age of 
patients (GBMs<60 years, median 158 IU/dL, IQR: 112–206; 
MNGs<60 years, median 109 IU/dL, IQR: 93–163; 
GBMs>60 years, median 231 IU/dL, IQR: 162–304; 
MNGs>60 years, median 143 IU/dL, IQR: 104–173, 
P < 0.05,) and furthermore, a statistically significant dif-
ference in VWF:Ag levels was observed in GBMs above 
60 years of age, compared to younger (260 ± 145 IU/
dL, vs. 196 ± 137 IU/dL, P < 0.05, Fig. 1B). In patients 
with GBMs, VWF:Ag levels were also linearly correlated 
with the tumor volume (r = 0.27; P = 0.04), while no 
correlation was found with the degree of MGMT promoter 
methylation.
Survival analysis in patients with GBM
During the follow- up, 34 patients (60%) died after a 
median of 0.8 years (IQR: 0.4–1.4) from diagnosis with 
a mortality rate of 0.4 per person- year (95% CI 0.3–0.6). 
The main characteristics of this patient group are shown 
in Table 2. The genetic and epigenetic pattern of these 
patients was characterized by the presence of 1p/19q code-
letion in two patients (3%), an unmethylated status of 
MGMT promoter in 28 (49%), and a wild- type IDH1/2 
Table 1. Main characteristics of the 80 patients included in the study.
Patients with GBM 
(n = 57)
Patients with MNG 
(n = 23)
Male sex (%) 41 (62) 11 (48)
Median age at study  
entry, years (IQR)
61 (48–71) 66 (54–71)
Median follow- up 
duration1, years (IQR)
0.9 (0.4–1.5) 2.5 (1.6–2.8)
Patients alive at the  
end of follow- up (%)
21 (36) 23 (100)
IQR: interquartile range; GBM, glioblastoma; MNG, meningiomas.
1Follow- up duration was calculated from the date of diagnosis to date 
of death or last follow- up visit whichever came first.
Figure 1. VWF:Ag plasma levels in MNG and GBM patients. (A) The box- plots represent the interquartile range with median (central line); the 
whiskers represent the range of MNGs and GBMs measured in our patient cohort; (B) the box- plot represent the VWF:Ag levels in MNGs and GBMs 
above 60 years of age, compared to younger. The dotted lines depict the interquartile ranges (IQR) of (VWF):Ag plasma levels in normal subjects. 
Mngs, Meningiomas. *P < 0.05; **P < 0.01. GBM, glioblastoma; MNG, meningiomas; VWF, von Willebrand Factor.
A B
1787© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
vWF as Circulating Biomarker in GlioblastomaG. Marfia et al.
in 39 (68%). The cumulative 1- year survival was signifi-
cantly shorter in patients with vWF:Ag levels > 200 IU/
dL (43 vs. 73% in patients with VWF:Ag < 200 IU/dL; 
P = 0.009; Fig. 2) and similar results were found com-
paring patients with VWF:Ag levels above or below 165 
and 250 IU/dL (48 vs. 78% for both comparisons; P = 0.02 
and P = 0.001, respectively) as reported for the whole 
study population. The cumulative 1- year survival was 
shorter in patients with a tumor volume >25 cm3 (46 
vs. 83% in those with tumor volume <25 cm3; P = 0.02). 
No difference in the survival rate was found by compar-
ing patients with methylated and unmethylated MGMT 
promoter. By univariate Cox regression analysis, VWF:Ag 
levels >200 IU/dL (cHR 2.5; 95% CI: 1.2–5.1), age >60 years 
at time of surgery (cHR 2.6; 95% CI: 1.4–4.9), preopera-
tive KPS <70 (cHR 2.5; 95% CI: 1.2–5.5), a tumor volume 
>25 cm3 (cHR 2.1; 95% CI: 1.1–4.2), and wild- type IDH1/2 
(cHR 4.8; 95% CI: 1.3–16.9) resulted risk factors of 
decreased survival.
Age- matched survival analysis
Considering that VWF:Ag levels were strongly correlated 
with age, a subgroup analysis was performed including 
23 patients with GBMs age- matched with 23 patients with 
MNGs.
The median age was 66 years in both groups (IQR: 
56–72 and 54–71 in GBMs and MNGs, respectively). 
VWF:Ag levels were still significantly higher in patients 
with GBM as compared with MNG patients (median: 133 
vs. 237 IU/dL, IQR: 101–190 vs. 182–453, respectively; 
P < 0.0001). Also in this subgroup of patients, the 1- year 
cumulative survival was significantly decreased in patients 
with VWF:Ag levels > 200 IU/dL (40 vs. 86% in those 
with VWF:Ag levels < 200 IU/dL; P = 0.001) and similar 
results were obtained by comparing patients with VWF:Ag 
levels above or below 165 or 250 IU/dL (61 vs. 84%, 
P = 0.03 and 33 vs. 84%, P = 0.0001, respectively). By 
univariate Cox regression analysis, VWF:Ag 
levels > 200 IU/dL were associated with reduced survival 
with a cHR of 5.8 (95% CI: 1.9–17.8).
Discussion
Gliomas are the most common type of primary tumors 
of the central nervous system and among them, GBM is 
the most common primary malignant brain tumor in 
adults and with the worst prognosis [21]. Several clinical 
predictors of survival have been identified, such as age, 
preoperative functional status, and tumor extent [22]. In 
addition, some genetic and epigenetic features may be 
used as prognostic factors [2, 3]. Nevertheless, despite 
many efforts to treat this disease, the mortality rate remains 
high, recurrence seems to be the rule, and still the out-
come is invariably fatal. Malignant transformation results 
from the sequential accumulation of genetic alterations 
and abnormal regulation of growth factors signaling, 
including proangiogenic factors. GBMs are highly vascu-
larized tumors and the process of angiogenesis is progres-
sive throughout tumor development. Elevated levels of 
VEGF in serum/plasma of patients with gliomas seem to 
correlate with the microvascular density of the tumoral 
lesions [23] and current trials on GBMs with antiangio-
genic agents, have shown a higher response rate and 
Table 2. Main characteristics of the 57 patients with GBM included in 
the study.
Characteristic
Median age at study entry, years (IQR) 62 (50–71)
Male sex (%) 36 (63)
Median VWF:Ag levels, IU/dL (IQR) 190 (141–294)
Median tumor volume, cm3 (IQR) 25.3 (8–46)
Median preoperative KPS, (IQR) 80 (70–90)
Median percentage of MGMT promoter methylation, 
(IQR)
8 (4–26)
IQR: interquartile range; VWF: von Willebrand factor; KPS: Karnofsky 
Performance Status; MGMT: O(6)- methylguanine- DNA methyltrans-
ferase; GBM, glioblastoma.
Figure 2. Survival rates among patients with GBM compared on the 
basis of VWF:Ag levels in plasma.Graph showing Kaplan–Meier 
estimates of overall survival in GBM patients who underwent gross total 
resection followed by standard- of- care radiation therapy and 
chemotherapy. The cumulative 1- year survival in GBM patients with 
VWF:Ag levels >200 IU/dL (light gray line) was significantly shorter as 
compared with patients with VWF:Ag levels < 200 IU/dL (dark gray line) 
(43 vs. 73%; P = 0.009).GBM, glioblastoma; VWF, von Willebrand 
Factor
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6- month progression free survival [24], but rather modest 
effects on overall survival [25]. Plasma VWF, mainly deriv-
ing from endothelial cells, is often raised in patients with 
cancer and this may be due to an increased release in 
the neoplastic microenvironment where neoangiogenesis 
is a common feature. Furthermore, VWF is essential for 
WPB formation which contain several molecules involved 
in angiogenesis such as P- selectin, angiopoietin- 2, and 
interleukin- 8 [26]. In addition, VWF is able to control 
VEGF signaling through multiple mechanisms involving 
both integrin αvβ3 and angiopoietin 2 [27], suggesting 
a role for VWF in angiogenesis modulation [10]. In our 
study, patients with GBM had higher plasma VWF:Ag 
levels than those with benign expansive brain lesions. At 
variance with many of these, we took patients with benign 
brain expansive lesions as controls rather than healthy 
subjects considering that VWF:Ag usually raise in all 
patients with both benign and malignant neoplastic diseases 
[28], so rendering the finding of significantly higher levels 
in malignant gliomas more robust.
Increased VWF levels were associated with a threefold 
higher risk of death in patients with GBMs; however, since 
GBMs often occur in elderly individuals, the increase in 
VWF levels observed in this patient group could have 
been confounded by age, and indeed in the multivariate 
model, the risk associated with high VWF levels was no 
longer significant. For this reason, we performed a suba-
nalysis in a group of age- matched GBMs and MNGs, 
confirming that VWF levels were significantly related with 
survival irrespective of age. For the same reason, since 
VWF tend to be higher in individuals with non- O blood 
groups [20], we checked that the distribution of ABO 
blood groups was similar between patients with GBMs 
and those with MNGs in order to rule out that the increased 
VWF levels were not attributable to a skewed blood group 
distribution. Indeed, as reported by Akin, differences in 
VWF levels between O and non- O groups are more reli-
able for VWF values lower than 50 IU/dL, while in our 
patients, VWF levels are always higher, so as not to show 
significant differences between ABO groups [29].
In patients with GBM, survival was inversely related 
to VWF:Ag levels and tumor volume. However, MNGs 
that are high vascularized tumors have a benign course 
and much lower mortality rates [30]. In a series of 28 
patients with head and neck cancer, VWF levels were 
reported to be significantly higher in patients who died 
than in those who survived [31]. In another series, VWF 
levels were significantly higher in 30 patients with malig-
nant brain tumors as compared with 30 patients with 
benign brain tumors [32] but no regression analysis was 
performed to ascertain their prognostic value. All patients 
with GBM in our study had supraphysiological VWF:Ag 
levels and the higher was the VWF level the shorter was 
the survival rendering VWF:Ag levels a putative prognostic 
factor. Such a prognostic role for VWF has been shown 
in patients with other type of cancer, being high VWF 
levels associated with disease stage, [33–37], presence of 
metastases and/or lymph node status [33, 34, 36, 37], 
tumor size and residual disease after surgery [35]. All in 
all, this study showed a significantly reduced survival in 
patients with GBMs and preoperative high levels of VWF:Ag 
in plasma irrespective of age. However, whether this find-
ing is associated with the degree of angiogenesis within 
the neoplastic tissue or an abnormal or genetically deregu-
lated pattern of VWF synthesis remains to be established 
by means of the experimental studies on GBM vascular 
compartment.
However, it should be emphasized that VWF is an 
acute phase inflammatory marker and it is, therefore, often 
difficult to establish exactly whether raised levels are causal 
or simply an epiphenomenon of the underlying cancer- 
associated inflammatory process. For this reason, further 
studies are necessary to elucidate the aspects regarding 
the molecular pathways supporting the angiogenic role 
of VWF, although this possibility does not impinge upon 
our findings on the negative predictive values of this easily 
measurable plasma marker to better define prognosis and 
clinical outcome.
Acknowledgments
The study was partially supported by a grant from the 
Italian Ministry of Health, Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico (GRANT#5x1000- 2011).
Conflict of Interest
The authors declare no conflict of interest.
References
 1. Ohgaki, H., and P. Kleihues. 2005. Population- based 
studies on incidence, survival rates, and genetic 
alterations in astrocytic and oligodendroglial gliomas. J. 
Neuropathol. Exp. Neurol. 64:479–489.
 2. van den Bent, M. J., H. J. Dubbink, M. Sanson, C. R. 
van der Lee-Haarloo, M. Hegi, J. W. Jeuken, et al. 
2009. MGMT promoter methylation is prognostic but 
not predictive for outcome to adjuvant PCV 
chemotherapy in anaplastic oligodendroglial tumors: a 
report from EORTC Brain Tumor Group Study 26851. 
J. Clin. Oncol. 27:5881–5886.
 3. van den Bent, M. J., H. J. Dubbink, Y. Marie, A. A. 
Brandes, M. J. Taphoorn, P. Wesseling, et al. 2010. 
IDH1 and IDH2 mutations are prognostic but not 
predictive for outcome in anaplastic oligodendroglial 
tumors: a report of the European Organization for 
1789© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
vWF as Circulating Biomarker in GlioblastomaG. Marfia et al.
Research and Treatment of Cancer Brain Tumor Group. 
Clin. Cancer Res. 16:1597–1604.
 4. Weller, M., J. Felsberg, C. Hartmann, H. Berger, J. P. 
Steinbach, J. Schramm, et al. 2009. Molecular predictors 
of progression- free and overall survival in patients with 
newly diagnosed glioblastoma. A prospective 
translational study of the German glioma network. J. 
Clin. Oncol. 27:5743–5750.
 5. Dang, L., D. W. White, S. Gross, B. D. Bennett, M. A. 
Bittinger, E. M. Driggers, et al. 2009. Cancer- associated 
IDH1 mutations produce 2- hydroxyglutarate. Nature 
462:739–744.
 6. Esteller, M., J. Garcia-Foncillas, E. Andion, S. N. 
Goodman, O. F. Hidalgo, V. Vanaclocha, et al. 2000. 
Inactivation of the DNA- repair gene MGMT and the 
clinical response of gliomas to alkylating agents. N. 
Engl. J. Med. 343:1350–1354.
 7. Leon, S. P., R. D. Folkerth, and P. Black. 1996. 
Microvessel density is a prognostic indicator for patients 
with astroglial brain tumors. Cancer 77:362–372.
 8. Syed, P., S. Gupta, S. Choudhary, N. G. Pandala, A. 
Atak, A. Richharia, et al. 2015. Autoantibody profiling 
of glioma serum samples to identify biomarkers using 
human proteome arrays. Sci. Rep. 5: 13895.
 9. Zhao, H., C. Hou, A. Hou, and D. Zhu. 2016. 
Concurrent expression of VEGF- C and Neuropilin- 2 Is 
correlated with poor prognosis in glioblastoma. Tohoku 
J. Exp. Med. 238:85–91.
10. Randi, A. M., M. A. Laffan, and R. D. Starke. 2013. 
Von Willebrand Factor, angiodysplasia and angiogenesis. 
Mediterr. J. Hematol. Infect. Dis. 5:e2013060.
11. Yang, X., H. J. Sun, Z. R. Li, H. Zhang, W. J. Yang, B. 
Ni, et al. 2015. Gastric cancer- associated enhancement 
of von Willebrand factor is regulated by vascular 
endothelial growth factor and related to disease severity. 
BMC Cancer 21:80–86.
12. Yang, X., H. J. Sun, Z. R. Li, H. Zhang, W. J. Yang, B. 
Ni, et al. 2015. Gastric cancer- associated enhancement 
of von Willebrand factor is regulated by vascular 
endothelial growth factor and related to disease severity. 
BMC Cancer 15:80.
13. Sporn, L. A., V. J. Marder, and D. D. Wagner. 1986. 
Inducible secretion of large, biologically potent von 
Willebrand factor multimers. Cell 46:185–190.
14. Floyd, C. M., K. Irani, P. D. Kind, and C. M. Kessler. 
1992. von Willebrand factor interacts with malignant 
hematopoietic cell lines: evidence for the presence of 
specific binding sites and modification of von 
Willebrand factor structure and function. J. Lab. Clin. 
Med. 119:467–476.
15. Nierodzik, M. L., A. Klepfish, and S. Karpatkin. 1995. 
Role of platelets, thrombin, integrin IIb- IIIa, fibronectin 
and von Willebrand factor on tumor adhesion in vitro 
and metastasis in vivo. Thromb. Haemost. 74:282–290.
16. Johnson, M. D., C. L. Vnencak-Jones, S. A. Toms, P. 
M. Moots, and R. Weil. 2003. Allelic losses in 
oligodendroglial and oligodendroglioma- like neoplasms: 
analysis using microsatellite repeats and polymerase 
chain reaction. Arch. Pathol. Lab. Med. 127:1573–1579.
17. Quillien, V., A. Lavenu, M. Sanson, M. Legrain, P. 
Dubus, L. Karayan-Tapon, et al. 2014. Outcome- based 
determination of optimal pyrosequencing assay for 
MGMT methylation detection in glioblastoma patients. 
J. Neurooncol. 116:487–496.
18. Kothari, R. U., T. Brott, J. P. Broderick, W. G. Barsan, 
L. R. Sauerbeck, M. Zuccarello, et al. 1996. The ABCs 
of measuring intracerebral hemorrhage volumes. Stroke 
27:1304–1305.
19. Stupp, R., A. F. Hottinger, M. J. van den Bent, P. Y. 
Dietrich, and A. A. Brandes. 2008. Frequently asked 
questions in the medical management of high- grade 
glioma: a short guide with practical answers. Ann. 
Oncol. 19:vii209–vii216.
20. Gallinaro, L., M. G. Cattini, M. Sztukowska, R. Padrini, 
F. Sartorello, E. Pontara, et al. 2008. A shorter von 
Willebrand factor survival in O blood group subjects 
explains how ABO determinants influence plasma von 
Willebrand factor. Blood 111:3540–3545.
21. Louis, D. N., H. Ohgaki, O. D. Wiestler, W. K. 
Cavenee, P. C. Burger, A. Jouvet, et al. 2007. The 2007 
WHO classification of tumours of the central nervous 
system. Acta Neuropathol. 114:97–109.
22. Gorlia, T., M. J. van den Bent, M. E. Hegi, R. O. 
Mirimanoff, M. Weller, J. G. Cairncross, et al. 2008. 
Nomograms for predicting survival of patients with 
newly diagnosed glioblastoma: prognostic factor analysis 
of EORTC and NCIC trial 26981- 22981/CE.3. Lancet 
Oncol. 9:29–38.
23. Takano, S., Y. Yoshii, S. Kondo, H. Suzuki, T. Maruno, 
S. Shirai, et al. 1996. Concentration of vascular 
endothelial growth factor in the serum and tumor tissue 
of brain tumor patients. Cancer Res. 56:2185–2190.
24. Taylor, J., and E. R. Gerstner. 2013. Anti- angiogenic 
therapy in high- grade glioma (treatment and toxicity). 
Curr. Treat Options Neurol. 15:328–337.
25. Soda, Y., C. Myskiw, A. Rommel, and I. M. Verma. 
2013. Mechanisms of neovascularization and resistance 
to anti- angiogenic therapies in glioblastoma multiforme. 
J. Mol. Med. (Berlin, Germany) 91: 439–448.
26. Metcalf, D. J., T. D. Nightingale, H. L. Zenner, W. W. 
Lui-Roberts, and D. F. Cutler. 2008. Formation and 
function of Weibel- Palade bodies. J. Cell Sci. 121:19–27.
27. Starke, R. D., F. Ferraro, K. E. Paschalaki, N. H. 
Dryden, T. A. McKinnon, R. E. Sutton, et al. 2011. 
Endothelial von Willebrand factor regulates angiogenesis. 
Blood 117:1071–1080.
28. Röhsig, L. M., D. C. Damin, S. D. Stefani, C. G. Jr 
Castro, I. Roisenberg, and G. Schwartsmann. 2001. von 
1790 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
G. Marfia et al.vWF as Circulating Biomarker in Glioblastoma
Willebrand factor antigen levels in plasma of patients 
with malignant breast disease. Braz. J. Med. Biol. Res. 
34:1125–1129.
29. Akin, M., C. Balkan, D. Y. Karapinar, and K. Kavakli. 
2012. The influence of the ABO blood type on the 
distribution of von Willebrand factor in healthy children 
with no bleeding symptoms. Clin. Appl. Thromb. 
Hemost. 18:316–319.
30. Lamszus, K. 2004. Meningioma pathology, genetics 
and biology. J. Neuropathol. Exp. Neurol. 
63:275–286.
31. Sweeney, J. D., K. M. Killion, C. F. Pruet, and M. B. 
Spaulding. 1990. von Willebrand factor in head and 
neck cancer. Cancer 66:2387–2389.
32. Böhm, M., R. Gerlach, W. D. Beecken, T. Scheuer, I. 
Stier-Brück, and I. Scharrer. 2003. ADAMTS- 13 activity 
in patients with brain and prostate tumors is mildly 
reduced, but not correlated to stage of malignancy and 
metastasis. Thromb. Res. 111:33–37.
33. Wang, W. S., J. K. Lin, T. C. Lin, T. J. Chiou, J. H. 
Liu, C. C. Yen, et al. 2005. Plasma von Willebrand 
factor level as a prognostic indicator of patients with 
metastatic colorectal carcinoma. World J. Gastroenterol. 
11:2166–2170.
34. Zietek, Z., I. Iwan-Zietek, R. Paczulski, M. Kotschy, and 
Z. Wolski. 1996. von Willebrand factor antigen in blood 
plasma of patients with urinary bladder carcinoma. 
Thromb. Res. 83:399–402.
35. Gadducci, A., U. Baicchi, R. Marrai, V. Facchini, B. del 
Bravo, P. V. Fosella, et al. 1993. Pretreatment plasma 
levels of fibrinopeptide- A (FPA), D- dimer (DD), and 
von Willebrand factor (vWF) in patients with operable 
cervical cancer: influence of surgical- pathological stage, 
tumor size, histologic type, and lymph node status. 
Gynecol. Oncol. 49:354–358.
36. Gadducci, A., U. Baicchi, R. Marrai, B. Del Bravo, P. 
V. Fosella, and V. Facchini. 1994. Pretreatment plasma 
levels of fibrinopeptide- A (FPA), D- dimer (DD), and 
von Willebrand factor (VWF) in patients with ovarian 
carcinoma. Gynecol. Oncol. 53:352–356.
37. Paczuski, R., A. Bialkowska, M. Kotschy, D. Burduk, 
and S. Betlejewski. 1999. von Willebrand factor in 
plasma of patients with advanced stages of larynx 
cancer. Thromb. Res. 95:197–200.
